ARTICLE | Clinical News
Epclusa sofosbuvir/velpatasvir regulatory update
July 18, 2016 7:00 AM UTC
The European Commission and Health Canada approved Epclusa sofosbuvir/velpatasvir from Gilead to treat chronic HCV genotypes 1-6 infection with or without cirrhosis. Epclusa is indicated in combinatio...